UP 27522
Latest Information Update: 18 Nov 2019
Price :
$50 *
At a glance
- Originator UPSA
- Class Antihypertensives
- Mechanism of Action Angiotensin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 24 Sep 1997 No-Development-Reported for Hypertension in France (PO)
- 20 Mar 1995 New profile
- 20 Mar 1995 Preclinical development for Hypertension in France (PO)